Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Circulation

• Publication date

  2002-03-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/HC1102.105261PMID 11901048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overview of the results of recent beta blocker trials.

  2001cited by this paper
• Sympathetic overactivity and arterial hypertension in renal failure.

  2001cited by this paper
• Premature cardiovascular disease in chronic renal failure.

  2000cited by this paper
• Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors?

  2000cited by this paper
• Predictions for future growth of ESRD prevalence

  2000cited by this paper
• How to assess sympathetic activity in humans.

  1999cited by this paper
• Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy.

  1999cited by this paper
• Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators.

  1999cited by this paper
• The kidney and the neurogenic control of blood pressure in renal disease.

  1999cited by this paper
• Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.

  1999cited by this paper
• Sympathetic activation in the pathogenesis of hypertension and progression of organ damage.

  1999cited by this paper
• VI. Causes of death in ESRD.

  1999cited by this paper
• Excerpts from United States Renal Data System 1999 Annual Data Report.

  1999cited by this paper
• High-performance liquid chromatographic method for measuring total plasma homocysteine levels.

  1998cited by this paper
• On the epidemic of cardiovascular disease in patients with chronic renal disease and progressive renal failure: a first step to improve the outcomes.

  1998cited by this paper
• A limited renal injury may cause a permanent form of neurogenic hypertension.

  1998cited by this paper
• Antihypertensive drugs, dietary salt, and renal protection: how low should you go and with which therapy?

  1998cited by this paper
• Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

  1998cited by this paper
• Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.

  1996cited by this paper
• Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.

  1996cited by this paper
• The prognostic importance of left ventricular geometry in uremic cardiomyopathy.

  1995cited by this paper
• Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.

  1994cited by this paper
• 114 Plasma metanephrines in the diagnosis of pheochromocytoma

  1993cited by this paper
• Sympathetic overactivity in patients with chronic renal failure.

  1992cited by this paper
• Plasma free, sulfo- and glucuro-conjugated catecholamines in uremic patients.

  1986cited by this paper
• Norepinephrine-related mechanism in hypertension accompanying renal failure.

  1985cited by this paper
• Plasma norepinephrine, epinephrine, and dopamine levels in end-stage renal disease. Effect of hemodialysis.

  1985cited by this paper
• Plasma noradrenaline and blood pressure in uremia.

  1985cited by this paper
• Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.

  1984cited by this paper
• Sympathetic nervous system hyperactivity in maintenance hemodialysis patients.

  1982cited by this paper
• Mechanisms of autonomic nervous system dysfunction in uremia.

  1981cited by this paper
• Catecholamines in peripheral venous plasma in patients on chronic haemodialysis.

  1978cited by this paper
• Influence of ultrafiltration on plasma renin activity and adrenergic system.

  1978cited by this paper
• Competitive effects of hypokalemia and volume depletion on plasma renin activity, aldosterone and catecholamine concentrations in hemodialysis patients.

  1977cited by this paper
• Red blood cell catechol-o-methyl transferase, plasma catecholamines and renin in renal failure.

  1976cited by this paper
• Plasma noradrenaline levels in regular haemodialysis patients.

  1976cited by this paper
• The Natural history of chronic bronchitis and emphysema: An eight-year study of early chronic obstructive lung disease in working men in London

  1976cited by this paper
• CIRCULATION

  1964cited by this paper

• Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment.

  2026cites this paper
• Urine and plasma metanephrine concentrations in cats with chronic kidney disease: characterization and correlation with biomarkers of renal function.

  2026cites this paper
• Resveratrol improves contractile dysfunction, cell viability and oxidative stress in adult rat cardiomyocytes exposed to norepinephrine via SOD/FOXO1

  2026cites this paper
• Renalase, dopamine, and norepinephrine as markers for the development of hypertension in CKD patients

  2025cites this paper
• Endovascular renal denervation for the treatment of hypertension

  2025cites this paper
• Failure of Antihypertensive Treatment to Restore Normal Sympathetic Activity

  2025cites this paper
• Renal dysfunction in patients with resistant hypertension: association with clinical profile and fat depots

  2025cites this paper
• Sympathetic Responses to Antihypertensive Treatment Strategies

  2025cites this paper
• Safety and Efficacy of Renal Denervation for the Treatment of Resistant Hypertension in Patients with Chronic Kidney Disease: A Narrative Review of the Literature

  2025influential citation
• High Heart Rate, Sympathetic Overdrive, And Cardiovascular Risk In Hypertension.

  2025cites this paper
• Renal Denervation Improves Uremic Cardiomyopathy in Rats With Chronic Kidney Disease

  2025cites this paper
• Should We Use Renin–Angiotensin-System Inhibitors As a First-Line Therapy for the Management of Hypertension in Patients Receiving Hemodialysis?

  2025cites this paper
• Correction of certain pathophysiological components of the cardiovascular-renal metabolic syndrome (part two): The role of moxonidine

  2025cites this paper
• Outcomes of KDIGO-Defined CKD in U.S. Veterans With HFpEF, HFmrEF, and HFrEF.

  2025cites this paper
• Autonomic Dysfunction and Inflammation in CKD: A High-Risk Pathway.

  2024cites this paper
• Impact of sympathetic hyperactivity induced by brain microglial activation on organ damage in sepsis with chronic kidney disease

  2024cites this paper
• Autonomic and Vascular Function in Cardiovascular Health with Insights from COVID-19

  2024cites this paper
• Reliability of heart rate in reflecting cardiac sympathetic overdrive in type 2 diabetes mellitus

  2024cites this paper
• Risk Factors of Chronic Kidney Disease Progression: Between Old and New Concepts

  2024cites this paper
• Sex Differences in Sympathetic Transduction in Black and White Adults: Implications for Racial Disparities in Hypertension and Cardiovascular Disease Risk.

  2024cites this paper
• Association of stress hormones and the risk of cardiovascular diseases systematic review and meta-analysis

  2024cites this paper
• Renal Denervation in End-Stage Renal Disease: Current Evidence and Perspectives

  2024cites this paper
• High blood pressure with elevated resting heart rate: a high risk “Sympathetic” clinical phenotype

  2023cites this paper
• Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial

  2023cites this paper
• Impact of Impaired Kidney Function on Arrhythmia-Promoting Cardiac Ion Channel Regulation

  2023cites this paper
• Echocardiographic manifestations in end-stage renal disease

  2023cites this paper
• Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease

  2023cites this paper
• Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association

  2023cites this paper
• Sympathetic modulation as a goal of antihypertensive treatment: from drugs to devices

  2023cites this paper
• Effects of Nondipping Blood Pressure Changes: A Nephrologist Prospect

  2023cites this paper
• Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease

  2023cites this paper
• DISRUPTION OF SYMPATHETIC OUTFLOW TO INTRA-ABDOMINAL ORGANS EMULATES THE METABOLIC EFFECTS OF SLEEVE GASTRECTOMY IN OBESE MICE

  2023cites this paper
• Exercise modulates sympathetic and vascular function in chronic kidney disease

  2023cites this paper
• Diagnosis and treatment of hypertension in dialysis patients: a systematic review

  2023cites this paper
• EARLY MORNING HEMODYNAMIC CHANGES AND LEFT VENTRICULAR HYPERTROPHY AND MORTALITY IN HEMODIALYSIS PATIENTS

  2022cites this paper
• The arterial stiffness changes in hemodialysis patients with chronic kidney disease: The impact on mortality.

  2022cites this paper
• Effect of angiotensin converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis.

  2022cites this paper
• Heart rate thresholds for cardiovascular risk and sympathetic activation in the metabolic syndrome

  2022cites this paper
• Heart Rate Variability-Guided Training for Improving Mortality Predictors in Patients with Coronary Artery Disease

  2022cites this paper
• Sympathetic activation and heart rate thresholds for cardiovascular risk in chronic kidney disease

  2022cites this paper
• Renal denervation in patients with chronic kidney disease: current evidence and future perspectives

  2022cites this paper
• Cardiopulmonary function during exercise in heart failure with reduced ejection fraction following baroreflex activation therapy

  2022cites this paper
• Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease

  2022cites this paper
• Hypertension in chronic kidney disease: What lies behind the scene

  2022cites this paper
• Antihypertensive Therapie bei CKD-Stadium 5

  2022cites this paper
• Brain fog in neuropathic postural tachycardia syndrome may be associated with autonomic hyperarousal and improves after water drinking

  2022cites this paper
• Physiological Mechanisms of Hypertension and Cardiovascular Disease in End-Stage Kidney Disease

  2022cites this paper
• Effects of renal sympathetic denervation on the course of congestive heart failure combined with chronic kidney disease: Insight from studies with fawn-hooded hypertensive rats with volume overload induced using aorto-caval fistula

  2021cites this paper
• Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation

  2021cites this paper
• Transdermal auricular vagus stimulation for the treatment of postural tachycardia syndrome.

  2021cites this paper
• Assessment of Renalase Levels in End-Stage Renal Disease Patients on Maintenance Hemodialysis

  2021cites this paper
• Predictive impacts of chronic kidney disease and cardiac sympathetic nervous activity on lethal arrhythmic events in chronic heart failure

  2021influential citation
• CENTRAL AND PERIPHERAL SYMPATHETIC ACTIVATION IN HEART FAILURE.

  2021cites this paper
• Clinical Relevance of the Sympathetic–Vascular Interactions in Health and Disease

  2021cites this paper
• Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease

  2021cites this paper
• Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial

  2021cites this paper
• Renal Deafferentation Prevents Progression of Hypertension and Changes to Sympathetic Reflexes in a Rabbit Model of Chronic Kidney Disease

  2021cites this paper
• Sympathetic Transduction in Humans: Recent Advances and Methodological Considerations.

  2021cites this paper
• Elevated heart rate and cardiovascular risk in hypertension.

  2021cites this paper
• Cardiovascular Disease and Inflammation

  2021cites this paper
• Novel strategies of hypertension management in chronic kidney disease

  2020cites this paper
• Heart Rhythm Complexity Predicts Long‐Term Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective Cohort Study

  2020cites this paper
• Evaluation of management and factors associated with hypertension control in hemodialysis patients at a tertiary-care hospital in Pakistan

  2020cites this paper
• Renal Denervation: Physiology, Scope, and Current Evidence

  2020cites this paper
• Exercise training ameliorates adrenergic control in spontaneously hypertensive rats

  2020cites this paper
• Sympathetic Overactivation in Patients With Essential Hypertension and Hepatic Iron Overload

  2020cites this paper
• Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis

  2020cites this paper
• Upstroke Time as a Novel Predictor of Mortality in Patients with Chronic Kidney Disease

  2020cites this paper
• Cardiovascular Benefits of Extended-Time Nocturnal Hemodialysis.

  2020cites this paper
• Approach and Management of Hypertension After Kidney Transplantation

  2020cites this paper
• Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers

  2020cites this paper
• Metabolic and non-traditional risk factors of death and cardiovascular events in aging patients with end-stage renal disease

  2020cites this paper
• Association between Mean Heart Rate and Recurrence Quantification Analysis of Heart Rate Variability in End-Stage Renal Disease

  2020cites this paper
• Limited reliability of heart rate as a sympathetic marker in chronic kidney disease

  2020cites this paper
• Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease

  2020cites this paper
• Differential sympathetic response to lesion-induced chronic kidney disease in rabbits.

  2020cites this paper
• Sympathetic Activation in Hypertensive Chronic Kidney Disease – A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?

  2020cites this paper
• Impact of sex and age on metabolism, sympathetic activity, and hypertension

  2020cites this paper
• Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis.

  2020cites this paper
• Electrocardiogram changes in patients with end stage renal disease on chronic haemodialysis

  2019influential citation
• Sympathetic activation in congestive heart failure: an updated overview

  2019cites this paper
• Evolving concepts in the pathogenesis of uraemic cardiomyopathy

  2019cites this paper
• Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients: a cohort study.

  2019cites this paper
• Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience

  2019cites this paper
• Factors associated with the risk of cardiovascular disease in family caregivers of people with dementia: a systematic review

  2019cites this paper
• Chromogranin A pathway: from pathogenic molecule to renal disease.

  2019influential citation
• Sex differences in sympathetic activity in obesity and its related hypertension

  2019cites this paper
• Sympathetic renal denervation for resistant hypertension : impact on blood pressure and on surrogate markers of target organ damage

  2019cites this paper
• Olmesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease

  2019cites this paper
• Cardiac Injury, Maladaptation, and Heart Failure Incidence

  2019cites this paper
• SGLT2 Inhibitor–Induced Sympathoinhibition

  2019cites this paper
• Arterial Stiffness in the Heart Disease of CKD.

  2019cites this paper
• Sympathetic Overdrive in Hypertension, The Role of Beta Blocker, Focus on Bisoprolol

  2019cites this paper
• White-coat hypertension and albuminuria; lessons from the Hisayama and Ohasama studies

  2018cites this paper
• Barorezeptoraktivierungstherapie

  2018cites this paper
• Polyphenols, Antioxidants and the Sympathetic Nervous System.

  2018cites this paper
• Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease

  2018cites this paper
• Eyeball pressure stimulation induces subtle sympathetic activation in patients with a history of moderate or severe traumatic brain injury.

  2018cites this paper
• Arrhythmia and Chronic Kidney Disease

  2018cites this paper
• A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.

  2018cites this paper